AbbVie Inc.
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading higher after AbbVie beat Q3 ear...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses s...
Latest News
1 day ago · seekingalpha.com
Emerson Among 14 Dividend Growth Companies To Announce Annual Dividend Increases In First Half Of NovemberEmerson is set to extend its dividend growth streak to 70 years, with a predicted 6.3–8.1% increase driven by a business transformation. EMR's shift to higher-margin Intelligent Devices and Software & Control segments supports a rebound in adjusted EPS, forecasted to grow 19% this year. Dividend growth across the broader group of long-term payers remains mostly mid-single digits, but several—including ADP, Assurant, and Atmos—are expected to announce 10%+ increases.
1 day ago · fool.com
AbbVie: 3 Key Takeaways for Long-Term InvestorsAbbVie raised full-year net revenue guidance to $67.8 billion. Skyrizi and Rinvoq delivered $6 billion in combined growth this year.
1 day ago · fool.com
Is AbbVie a Buy After Its Latest Earnings Report?Adjusted EPS nearly doubled, but most of that comes from last year's big research-deal charge, and underlying growth was closer to 17%. Skyrizi and Rinvoq now account for nearly half of AbbVie's revenue, which drives growth and concentrates risk.
2 days ago · seekingalpha.com
Dividend Champion, Contender, And Challenger Highlights: Week November 1A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
2 days ago · seekingalpha.com
AbbVie Inc. (ABBV) Q3 2026 Earnings Call TranscriptAbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript
2 days ago · marketbeat.com
What AbbVie (ABBV) Said on Its Q3 Earnings CallAbbVie NYSE: ABBV reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and neuroscience portfolios.
2 days ago · seekingalpha.com
AbbVie: Why I See More Upside After Q3AbbVie Inc. reported strong third-quarter results. ABBV's revenue increased 10.3% YoY, while non-GAAP EPS rose 105.4%. Skyrizi, AbbVie's IL-23 antagonist, generated $5.78 billion in sales, representing 22.7% year-over-year growth.
2 days ago · zacks.com
ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS ViewAbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.
2 days ago · zacks.com
Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 EarningsWhile the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
2 days ago · 247wallst.com
CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend.AbbVie just handed shareholders their latest raise while your CD rate sits frozen, but the comparison between a guaranteed payment and a growing dividend gets complicated fast once taxes, price swings, and reinvestment risk enter the picture.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ABBV